Processa Pharmaceuticals Inc Quick Ratio (PCSA) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Processa Pharmaceuticals Inc   (NASDAQ: PCSA)

Processa Pharmaceuticals Inc 's Quick Ratio

PCSA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.08 below Processa Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 424 other companies have achieved higher Quick Ratio than Processa Pharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1941 to 3773.

Explain Quick Ratio?
How much Cash & cash equivalents PCSA´s has?
What are PCSA´s Current Liabilities?




PCSA Quick Ratio (Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
(Jun 30 2025)
Q2
Y / Y Current Liabilities Change 16.49 % 60.55 % 53.21 % 43.62 % 40.49 %
Y / Y Cash & cash equivalent Change -97.17 % -41.63 % 364.77 % 118.17 % 24.51 %
Quick Ratio MRQ 0.08 0.85 2.48 3.6 3.39
PCSA's Total Ranking # 3773 # 1941 # 974 # 685 # 665
Seq. Current Liabilities Change 20.54 % -11.46 % 27.72 % -14.54 % 66.14 %
Seq. Cash & cash equivalent Change -88.39 % -69.46 % -12.23 % -9.06 % 139.44 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 425
Healthcare Sector # 852
Overall Market # 3773


Quick Ratio Statistics
High Average Low
26.03 4.11 0
(Sep 30 2021)   (Mar 31 2017)




Financial Statements
Processa Pharmaceuticals Inc 's Current Liabilities $ 2 Millions Visit PCSA's Balance sheet
Processa Pharmaceuticals Inc 's Cash & cash equivalent $ 0 Millions Visit PCSA's Balance sheet
Source of PCSA's Sales Visit PCSA's Sales by Geography


Cumulative Processa Pharmaceuticals Inc 's Quick Ratio

PCSA's Quick Ratio for the trailling 12 Months

PCSA Quick Ratio

(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
(Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 40.15 % 49.26 % 41.21 % 46.93 % 59.04 %
Y / Y Cash & cash equivalent TTM Growth -1.32 % 63.12 % 16.72 % -21.53 % -46.59 %
Quick Ratio TTM 1.64 2.55 2.98 2.67 2.33
Total Ranking TTM # 3919 # 3817 # 2861 # 3053 # 2949
Seq. Current Liabilities TTM Growth 4.21 % 10.27 % 11.96 % 8.92 % 10.99 %
Seq. Cash & cash equivalent TTM Growth -32.92 % -5.56 % 25.07 % 24.55 % 10.88 %


On the trailing twelve months basis Due to growth in Current Liabilities in the Q2 2026 to $2.39 millions, cumulative Quick Ratio decreased to 1.64 below the Processa Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Processa Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3817 to 3919.

Explain Quick Ratio?
How much Cash & cash equivalents PCSA´s has?
What are PCSA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 433
Healthcare Sector # 887
Within the Market # 3919


trailing twelve months Quick Ratio Statistics
High Average Low
17.45 3.73 0
(Mar 31 2022)   (Jun 30 2017)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Cytodyn inc   0.22 $ 11.852  Millions$ 53.727  Millions
Collegium Pharmaceutical Inc   0.22 $ 129.467  Millions$ 589.861  Millions
International Stem Cell Corporation  0.22 $ 1.089  Millions$ 4.984  Millions
Earth Science Tech Inc   0.22 $ 0.631  Millions$ 2.902  Millions
Viatris Inc   0.22 $ 1,368.700  Millions$ 6,345.800  Millions
Eli Lilly And Company  0.19 $ 8,950.000  Millions$ 47,741.000  Millions
Polomar Health Services, Inc.  0.18 $ 0.188  Millions$ 1.063  Millions
Tempest Therapeutics Inc   0.18 $ 0.779  Millions$ 4.450  Millions
Abbvie Inc   0.16 $ 6,569.000  Millions$ 41,642.000  Millions
Amneal Pharmaceuticals Inc   0.15 $ 136.280  Millions$ 883.187  Millions
Neonc Technologies Holdings Inc   0.15 $ 3.573  Millions$ 23.507  Millions
Jaguar Health Inc   0.15 $ 3.788  Millions$ 25.380  Millions
Alaunos Therapeutics Inc   0.14 $ 0.124  Millions$ 0.864  Millions
Cumberland Pharmaceuticals Inc   0.11 $ 3.862  Millions$ 35.193  Millions
Igc Pharma Inc   0.11 $ 0.354  Millions$ 3.287  Millions
Tuhura Biosciences Inc   0.11 $ 0.996  Millions$ 9.255  Millions
Gridai Technologies Corp  0.10 $ 1.380  Millions$ 14.146  Millions
Bioxcel Therapeutics Inc   0.09 $ 12.841  Millions$ 137.149  Millions
Galectin Therapeutics Inc   0.09 $ 13.275  Millions$ 151.619  Millions
Lftd Partners Inc   0.08 $ 0.304  Millions$ 3.648  Millions
Processa Pharmaceuticals Inc   0.08 $ 0.196  Millions$ 2.387  Millions
Cv Sciences Inc   0.05 $ 0.266  Millions$ 4.943  Millions
Citius Pharmaceuticals Inc   0.05 $ 17.008  Millions$ 333.952  Millions
Sunshine Biopharma Inc   0.05 $ 0.281  Millions$ 5.619  Millions
Hcw Biologics Inc   0.04 $ 0.741  Millions$ 18.648  Millions
China Pharma Holdings Inc  0.04 $ 0.305  Millions$ 7.682  Millions
Bioxytran Inc   0.03 $ 0.177  Millions$ 5.275  Millions
Cdt Equity Inc   0.03 $ 0.700  Millions$ 23.351  Millions
Shuttle Pharmaceuticals Holdings Inc   0.03 $ 0.102  Millions$ 3.481  Millions

Date modified: 2026-09-08T21:33:53+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.